Dixon Hughes Goodman Wealth Advisors’s Humacyte HUMA Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$48K	Buy	+6,750	New	+$39.3K	0.01%	313

Other funds holding HUMA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GIA

Gladstone Institutional Advisory Palm Beach Gardens, Florida $2.7B AUM 23.82% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's HUMA Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors opened a new position in Humacyte (HUMA) in Q1 2022: 6,750 shares worth $48K. The stake represents 0.01% of the portfolio and ranks #313 among its holdings.

70 funds tracked by Wall St. Rank hold HUMA as of Q1 2022.

Dixon Hughes Goodman Wealth Advisors held 6,750 shares of Humacyte worth $48K as of Q1 2022.
Humacyte was a new Dixon Hughes Goodman Wealth Advisors position in Q1 2022.
Humacyte made up 0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #313 holding.
70 funds tracked by Wall St. Rank held Humacyte as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.